Ipsen

BAKX Therapeutics is a company focused on developing innovative cancer treatments. It specializes in creating orally active therapeutics that target the mitochondrial apoptosis pathway, which plays a crucial role in cell death and cancer progression. By leveraging insights into the dynamic protein structures involved in this pathway, along with advanced structure-based drug design and computational simulations, BAKX aims to enhance the effectiveness and longevity of cancer therapies. The company's approach seeks to provide medical professionals with improved treatment options for cancer patients.

Pyxis Oncology, Inc. is a biotechnology company focused on developing antibody therapeutics that enhance the immune response against cancer. Founded in 2018 and based in Boston, Massachusetts, the company specializes in analyzing tumor antigen-specific tumor-infiltrating lymphocytes within hot tumors and tumor cell signaling pathways in cold tumors. This research informs the creation of novel antibody-based immunotherapies aimed at targeting difficult-to-treat cancers. Pyxis Oncology's goal is to develop next-generation therapeutics that not only kill tumor cells but also address the underlying issues that facilitate cancer's proliferation and immune evasion, ultimately improving the quality of life for patients.

Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.

Pyxis Oncology, Inc. is a biotechnology company focused on developing antibody therapeutics that enhance the immune response against cancer. Founded in 2018 and based in Boston, Massachusetts, the company specializes in analyzing tumor antigen-specific tumor-infiltrating lymphocytes within hot tumors and tumor cell signaling pathways in cold tumors. This research informs the creation of novel antibody-based immunotherapies aimed at targeting difficult-to-treat cancers. Pyxis Oncology's goal is to develop next-generation therapeutics that not only kill tumor cells but also address the underlying issues that facilitate cancer's proliferation and immune evasion, ultimately improving the quality of life for patients.

Clementia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Montreal, Canada, focused on developing innovative treatments for patients with ultra-rare bone disorders and other diseases characterized by high unmet medical needs. Founded in 2010, the company specializes in disease-modifying therapies, with its lead product candidate being palovarotene, an oral small molecule. Palovarotene has demonstrated significant potential in preventing abnormal bone formation and fibrosis across various tissues. The candidate is currently undergoing evaluation in the Phase III MOVE trial, targeting conditions such as fibrodysplasia ossificans progressive and multiple osteochondromas, as well as dry eye disease. Clementia's commitment to addressing debilitating health issues highlights its role in advancing treatment options for affected patients.

Merrimack Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 1993. The company focuses on the discovery, design, and development of innovative therapies for diseases related to autoimmunity and cancer. Its notable products include MM-093, aimed at treating rheumatoid arthritis and psoriasis, and MM-121, a human monoclonal antibody designed to inhibit the ErbB3 receptor signaling. Merrimack employs a systems biology approach, utilizing multidisciplinary capabilities to create predictive computational models of biological systems, particularly in cell signaling networks. Additionally, the company engages in partnerships with third parties to enhance the commercialization of its therapeutics.

Rhythm Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing peptide therapeutics for the treatment of rare genetic disorders, particularly those leading to life-threatening metabolic conditions. Its primary product candidate, setmelanotide, is a first-in-class melanocortin-4 receptor agonist currently undergoing Phase III clinical trials for obesity related to pro-opiomelanocortin and leptin receptor deficiencies, as well as Bardet-Biedl and Alström syndromes. Additionally, setmelanotide is in Phase II trials for various other genetic obesity disorders. The company is also advancing RM-853, an orally available ghrelin O-acyltransferase inhibitor, in preclinical development for Prader-Willi syndrome. Founded in 2008 and headquartered in Boston, Massachusetts, Rhythm Pharmaceuticals aims to address significant unmet medical needs in the realm of genetic metabolic disorders through innovative therapies.

Akkadeas Pharma srl, founded in 2007 and based in Milan, Italy, specializes in the production and sale of pharmaceutical products, food supplements, and medical devices aimed at alleviating symptoms and disturbances that affect patients' daily activities. The company's product line includes offerings such as OVERSAL, BBTONIK-500, PERGRILL, OVERSAL FOLIC, SKRIM 1G, and TROFIGARD. Additionally, Akkadeas Pharma distributes third-party products, enhancing its portfolio. The company primarily serves patients through family doctors and specialists, focusing on private healthcare expenditure. Their products originate from both proprietary development and collaborations with specialized companies, reflecting their commitment to improving individual well-being.

Rhythm Metabolic is the subsidiary of Rhythm Pharmaceuticals that develops setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway. It was established in 2013 and is headquartered in Boston, Massachusetts.

OctreoPharm Sciences GmbH is a biopharmaceutical company based in Berlin, Germany, specializing in the development of radiopharmaceuticals for the diagnosis and therapeutic management of neuroendocrine tumors. Established in 2010, the company is engaged in the clinical development of theranostic antagonistic peptides. Its key development products include OPS201, designed for tumor cell-selective internal peptide receptor radionuclide therapy utilizing 90Y or 177Lu, and OPS202, which is a new 68 gallium-labeled somatostatin receptor antagonist intended for positron emission tomography. As of mid-2015, OctreoPharm operates as a subsidiary of Ipsen S.A.

Canbex Therapeutics, Ltd. is a London-based company founded in 2005 that focuses on developing peripherally-acting cannabinoid agonists aimed at treating spasticity associated with multiple sclerosis and other neurodegenerative diseases. Spasticity is characterized by involuntary spasms and stiffness, which can significantly impact the quality of life for affected individuals. Canbex Therapeutics is committed to enhancing the treatment landscape for this debilitating symptom, striving to set a new standard for managing spasticity and improving patient outcomes in those suffering from these serious conditions.

Thesan Pharmaceuticals, Inc. is a preclinical biopharmaceutical company dedicated to the development of novel therapeutics for disorders of the skin. Until recently, there has been comparatively limited innovation in the field of dermatology, where many companies have focused on the reformulation of existing drugs often resulting in marginal patient benefit. In contrast, Thesan is focused on the discovery and development of New Chemical Entities that have the potential to provide significantly improved treatment options to patients.

Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.

Motus Therapeutics is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm investors include MPM Capital and New Enterprise Associates. The company is based in Boston, Massachusetts.

Motus Therapeutics is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm investors include MPM Capital and New Enterprise Associates. The company is based in Boston, Massachusetts.

Biomeasure, Inc., one of four research centers of the Ipsen Group to discover drugs in neuro-endocrinology, needed a multi-product, multi-purpose cGMP facility built on a fast track and a tight budget. Richmond started with a process to identify the goals of all Bio-measure stakeholders, continued with design & engineering coordination, achieved the budget through value engineering, and provided guaranteed costs & schedule. The results: 40,000 sf of cGMP manufacturing space, delivered in a short timeframe on a tight budget.

Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.

Ipsen Pharmaceuticals, Inc. provides pharmaceutical products.

Octagen Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of hemophilia and genetic disorders of the clotting process. It develops two variations of recombinant B domain deleted porcine factor VIII to avoid inactivation by flying below the radar screen of the immune system. The company was founded in 1997 and is based in Penn Valley, Pennsylvania. As of July 17, 2008, Octagen Corporation operates as a subsidiary of Ipsen S.A.

Tercica Inc., a biotechnology company, engages in the development and commercialization of therapeutics for the treatment of endocrine and metabolic diseases. Its products include Increlex, an rDNA origin injection for the long-term treatment of children with short stature due to severe primary IGFD; and Somatuline Depot, a lanreotide injection for the treatment of adults with acromegaly. Tercica Inc. has strategic partnerships with Genentech and Ipsen SA. The company was founded in 2002 and is based in Brisbane, California. As of October 16, 2008, Tercica Inc. operates as a subsidiary of Ipsen S.A.

Sterix Ltd operates as a biopharmaceutical company that provides research and development services.